1.On the cell of expressing human tissue kallikrein for gene modification, rigid envelope material with bi-directional flowability is coated.

在基因修飾的表達(dá)人組織激肽釋放酶的細(xì)胞上包覆著具有剛性和雙向流通性的包膜材料；

2.The invention relates to the pharmaceutical use of human urinary kallikrein in the treatment of acute coronary artery disease and pharmaceutical composition prepared by the method.

本發(fā)明涉及人尿激肽原酶用于治療急性冠狀動(dòng)脈疾病的藥物用途及按該方法制備的藥物組合物。

3.Therefore, it is possible that renal tissue kallikrein-bradykinin system is also released and activated by the stimulation of inflammation in sepsis.

因此，腎臟的組織型血管增滲酶也有可能被敗血癥引發(fā)的發(fā)炎反應(yīng)刺激而釋放出來(lái)，并產(chǎn)生作用。

4.CONCLUSION Human urinary kallikrein is effective and relatively safe in treatment of acute cerebral infarction in the vascular distribution of the internal carotid artery.

結(jié)論人尿激肽原酶治療急性頸內(nèi)動(dòng)脈系統(tǒng)腦梗死所致的神經(jīng)功能缺損，其效果及安全性良好。

5.The invention relates to the pharmaceutical use of human urinary kallikrein in the treatment of acute coronary artery disease and pharmaceutical composition prepared by the method.

本發(fā)明涉及人尿激肽原酶用于治療急性冠狀動(dòng)脈疾病的藥物用途及按該方法制備的藥物組合物。

6.Aim: To investigate the expression of human kallikrein 15 (KLK15) in the primary epithelial ovarian carcinoma and the clinical significance.

目的：研究上皮性卵巢癌組織中人類組織激肽釋放酶15 (KLK15)蛋白的表達(dá)。

7.Conclusion It is safe and effective by using urinary kallikrein on acute cerebral infarction.

結(jié)論尤瑞克林治療急性腦梗死安全有效。

8.It was presumed that KBP may playa role in the regulation of metabolism of tissue kallikrein on the level of biosynthesis and excretion.

推測(cè)KBP可能在合成和分泌的水平上，對(duì)組織激肽釋放酶的代謝及活性起調(diào)節(jié)作用。